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Abstract - Purpose. To evaluate the association between starting early treatment with anti-TNF and 
effectiveness as well as the possibility of applying therapeutic spacing in daily practice in patients with 
rheumatoid arthritis (RA). Methods. Observational, retrospective study conducted in two universitary 
hospitals in Spain. RA patients who received the first anti-TNF (adalimumab: ADA, etanercept: ETN or 
infliximab: IFX) during the study period (October 2006-2010) were included. Demographic data, time 
since diagnosis, disease activity (DAS28-ESR) and anti-TNF dosage were analyzed. Therapeutic objective 
was defined as DAS28<2.6. Also the response related to criteria of the European League Against 
Rheumatism (EULAR) was evaluated. Therapeutic spacing was defined as the use of a lower dose or a 
higher interval according to label doses. The main endpoint was to assess the association between the 
effectiveness and the moment when the anti-TNF therapy begins. The secondary target was to evaluate the 
association between RA activity at the beginning of treatment with anti-TNF and dose used. Results. 82 
patients were included. The prescription profile was: ADA (48.8%), ETN (31.7%) and IFX (19.5%). 
71.4% of patients treated with anti-TNF during the first year since diagnosis, 57.1% of those who started 
after 1-5 years and 30.6% of patients who started after 5 years were in remission when the study ended. 
De-escalation strategy was performed in 25.6% of patients: ETN (38.5%), ADA (20.0%) and IFX (18.8%). 
The patients treated with a higher dose according to label doses were: IFX (81%), ADA, (12.5%) and ETN 
(7.7%). Conclusions. Results suggest that early treatment with anti-TNF can achieve a higher percentage 
of remissions. Therapeutic spacing is established as a strategy that improves the efficiency in those patients 
in remission, being the ETN the anti-TNF most susceptible for spacing, although a relation between the 
early beginning with anti-TNF and the used dose was not found. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
______________________________________________________________________________________ 
 
INTRODUCTION 
 
Rheumatoid Arthritis (RA) is a chronic 
autoimmune disease characterized by 
inflammation and deterioration of the joints, 
which can produce a loss of functionality, 
reduces quality of life and enhances 
morbimortality  (1,2). Its prevalence is 0.5-1% 
(3), and it has a high social and economic impact. 
It is estimated that at 10 years from the beginning 
of the disease, more than 50% of patients will 
suffer a serious disability, and after 15 years just 
40% will be able to work (4). Early diagnosis of 
RA is fundamental for its management. Most 
patients will have suffered important radiologic 
damage in the first two years of the disease, and 
during this period the structural damage advances 
more rapidly (5,6). Therefore, the earlier the 
treatment starts, the higher the probability for 
managing the inflammatory process and reducing 
structural damage (7). 
The objective of treatment is to achieve 
complete remission (8). Just for prolonged 
evolution patients, a low activity state will be 
considered as target. Treatment allows pain 
control and prevents damage to articulations and 
the loss of functionality. It is recommended to 
start with disease-modifying antirheumatic drugs 
(DMARDs) as soon as the diagnostic has been 
established. Normally, treatment begins with 
methotrexate (MTX). However, in patients with 
high activity RA, in which a rapid progression 
can be expected, a combination of MTX and a 
biologic agent like an anti-TNF is used (9). 
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The use of biologic therapy (BT) in combination 
with DMARDs is more effective than using one 
or various DMARDs; maintaining remission for 
longer periods, with the possibility of increasing 
in dosage inteval or withdrawal of  BT (10,11). 
The spacing strategy reduces the number of 
administrations and therefore the cost associated 
to the drug. 
Our objective was to evaluate the association 
between the early beginning treatment with anti-
TNF and the effectiveness and possibility of 
applying a therapeutic spacing in daily practice 
in patients with RA. These results will allow for 
a better understanding and management of RA, 
since this is one of the first studies whit these 
goals. 
 
METHODS 
 
An observational, retrospective and multicenter 
(two university hospitals) study was carried out. 
Patients included were adults diagnosed with RA 
by the Rheumatology Department who were 
treated with the first anti-TNF between October 
2006 and October 2010. Patients who had an 
exposition to the drug lower than 6 months, 
receiving another biologic drug or participating 
in other clinical trials were excluded. 
 The studied anti-TNFs were: adalimumab 
(ADA), etanercept (ETN) and infliximab (IFX). 
The recorded variables were: demographics (age, 
gender and weight); date of RA diagnosis; 
previous treatment with MTX and its higher 
dose; which anti-TNF was used (type, dose, 
starting and ending dates of the treatment and if 
the treatment was suspended: date and reason); 
and the first and the last Disease Activity Score 
(DAS28) for each anti-TNF. 
 The efficacy variable was DAS28. 
Remission of the disease was considered if 
DAS28 <2.6. Also the response according to 
criteria of the European League Against 
Rheumatism (EULAR) was evaluated, collected 
in Table 1, which takes into account both the 
degree of reduction of DAS28 as the final 
absolute value (12). 
 The principal target was to evaluate the 
association between the effectiveness and the 
moment when the anti-TNF therapy began. This 
initial state was defined according to the first 
DAS28 and the time between RA diagnosis and 
the beginning of treatment with anti-TNF. 
 The secondary target was to evaluate the 
association between RA activity at the beginning 
of treatment with anti-TNF and the dose used, to 
assess if the spacing strategy depends on RA 
activity at the beginning of the BT. The 
therapeutic spacing was defined as the use of a 
lower dose or a higher interval according to label 
doses, randomly established by specialist’s 
criteria and the patient’s consent. 
 
STATISTICAL ANALYSIS 
 
Results have been shown with the mean and the 
standard deviation for normal variables and with 
the median and the percentiles for variables with 
a non-normal distribution. Kruskal-Wallis test 
was used for differences between non parametric 
variables; while differences between categorical 
variables were evaluated by Pearson’s χ2 or 
Fisher’s Exact. Correlation between categorical 
variables was performed by χ2 test and χ2 test of 
lineal tendency for ordinal variables. Spearman 
Rho test was used for the correlation between 
non parametric variables. 
The statistical analysis was performed by the 
statistical program SPSS 18.0. P<0.05 was 
considered as significant. 
 
RESULTS 
 
82 patients were included. The prescription 
profile was: ADA (48.8%), ETN (31.7%) and 
IFX (19.5%). The basal characteristics were 
recorded in table 2, where the only statistically 
significant differences were found in gender of 
IFX patients compared to ADA and ETN. 
 
 
 
 
Table 1. EULAR response (DAS28). 
Final DAS28  Decrease of the DAS28 regard to the basal value.  >1.2 0.6 - 1.2 >0.6 
<3.2 Good response Moderate response No response 
3.2-5.1 Moderate response Moderate response No response 
>5.1 Moderate response No response No response 
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Effectiveness data are recorded in table 3, 
where the only differences were found between 
ADA and IFX in patients with “moderate” and 
“none” EULAR response. 
 
Relation between the early beginning of anti- 
TNF therapy and its effectiveness (DAS28) 
 
Influence on the effectiveness of the time between 
diagnosis and beginning BT: 
 
The time between diagnosis and the first anti-
TNF and final DAS28 (r=0.300, p=0.011) and 
the time between diagnosis and RA final activity 
(r=0.355, p=0.002) showed a positive correlation. 
71.4% of patients treated with anti-TNF 
during the first year since diagnosis, 57.1% of 
those who started after 1-5 years and 30.6% of 
the ones who started after 5 years were in 
remission when the study ended. 
There was also correlation between the time 
since the diagnosis and the EULAR response 
(r=0.353, p=0.003) (Table 4). 
 
Influence of initial DAS28 on effectiveness: 
 
There was a positive correlation between the 
initial and final DAS28 (r=0.343, p=0.002) and 
between the initial and final RA activity 
(r=0.245, p=0.026). 
63.6% of patients treated with the first anti-
TNF with an initial DAS28<3.2, 51.4% of the 
ones that started with a DAS28: 3.2-5.1 and 
27.8% with an initial DAS28>5.1 were in 
remission at the end of the study. 
Remission percentages, at the end of the 
study, according to initial RA activity and time 
since diagnosis starting BT are shown in table 5.
 
 
Table 2. Basal characteristics between the anti-TNF. 
 ADA (n=40) ETN (n=26) IFX (n=16) 
Age (years) 57.7 (12.8) 52.3 (16.0) 59.6 (12.6) 
Gender (% women) 77.5 73.1 100.0 
Time since RA diagnosis (years) 4.4 (2.0, 8.2) 6.7 (1.3, 14.1) 7.2 (3.9, 15.8) 
Time with anti-TNF (years) 1.8 (0.8, 2.9) 2.6 (1.5, 3.4) 1.7 (0.9, 2.2) 
Initial DAS28  4.8 (1.2) 4.9 (1.5) 4.4 (1.4) 
RA initial activity (% 
patients) 
DAS28 <2.6 5.0 7.7 6.3 
DAS28: 2.6-3.2 5.0 7.7 12.5 
DAS28: 3.2-5.1 47.5 30.8 50.0 
DAS28 >5.1 42.5 53.8 31.3 
Previous treatment with MTX (% patients) 95.0 88.8 100.0 
Maximun dose of MTX (mg) 14.9 15.1 15.0 
Data are expressed as median (p25, p75) or mean (SD); ADA: adalimumab; ETN: etanercept; IFX: infliximab; 
MTX: methotrexate 
 
 
 
 
Table 3. Effectiveness data of the anti-TNFs. 
 ADA (n=40) ETN (n=26) IFX (n=16) 
Final DAS28  2.8 (1.3) 3.0 (1.5) 3.5 (2.0) 
RA final activity 
(% patients) 
DAS28 <2.6 50.0 34.6 37.5 
DAS28: 2.6-3.2 15.0 26.9 18.8 
DAS28: 3.2-5.1 30.0 30.8 18.8 
DAS28 >5.1 7.7 5.0 25.0 
Reduction of the DAS28 2.0 (1.2) 1.8 (2.0) 0.9 (2.0) 
Response of the 
EULAR 
(% patients) 
Good response 52.5 50.0 43.8 
Moderate response 40.0 26.9 6.3 
No response 7.5 23.1 50.0 
Suspension of the anti-TNF (% 
patients) 5.0 11.5 18.8 
Reason for suspension (% reason) 100 adverse effect 66.6 therapeutic failure, 33.3 adverse effect 
66.6 therapeutic failure, 
33.3 adverse effect 
Data are expressed as mean (SD); ADA: adalimumab; ETN: etanercept; IFX: infliximab 
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Table 4. Relation of the time between diagnosis and beginning of anti-TNF therapy and the EULAR response. 
 Time since the 
diagnosis <1 year 
(n=7) 
Time since the 
diagnosis 1-5 years 
(n=28) 
Time since the 
diagnosis >5 years 
(n=36) 
Good response (% patients) (n=37)  85.7 % 64.3 % 36.1% 
Moderate response (% patients) (n=22) 14.3 % 25.0% 38.9% 
No response (% patients) (n=12) 0.0 % 10.7% 25.0% 
 
  
Table 5. Percentage of patients in remission (DAS28<2.6) at the end of the study. 
 Time after diagnosis 
<1 year (n=7) 
Time after diagnosis 1-5 years 
(n=28) 
Time after diagnosis 
>5 years (n=36) 
Initial DAS28 <3.2 
(% patients in 
remission)  (n=10) 
100 % 100 % 75.0% 
Initial DAS28 3.2-5.1 
(% patients in 
remission)  (n=31) 
75.0 % 69.2% 28.6% 
Initial DAS28 ≥5.1 
(% patients in 
remission)  (n=30) 
50.0% 50.0% 7.1% 
 
 
 
Relation between the starting early of anti-
TNF treatment and the dose used 
 
Spacing strategy was performed in 25.6% of 
patients: ETN (38.5%), ADA (20.0%) and IFX 
(18.8%). The percentage of patients treated with 
a higher dose of IFX (according to the label 
dose) was considerably higher (81%) than ADA 
(12.5%) and ETN (7.7%). 
No differences were observed either between 
anti-TNFs doses with the initial DAS28 (p= 
0.628) or in the time between diagnosis and the 
first anti-TNF (p=0.670). Also, there was no 
correlation in drugs studied separately with this 
association. 
 
DISCUSSION 
 
Results suggest a better response based on 
DAS28 at early beginning with anti-TNFs, with 
a significant correlation in the time between 
diagnosis and the beginning of anti-TNF therapy. 
85.7% of patients treated with anti-TNF during 
the first year since the diagnosis reached “good 
response” (EULAR criteria) and 71.4% were in 
remission at the end of the study. Initial DAS28 
is related with response, as expected. 63.6% of 
patients treated with the first anti-TNF with a 
DAS28<3.2 reached remission, with a gradual 
decreasing of the percentage when bigger the 
initial DAS28 is. 
Currently, starting treatment with MTX is 
recommended. Moreover, it is known that the 
earlier the treatment starts the better the outcome. 
However, for early and aggressive RA, its 
combination with an anti-TNF is also 
recommended (8,9). In the PREMIER study (10) 
three different ways for beginning treatment 
were compared: MTX, ADA and MTX+ADA, 
and the combination therapy showed the best 
results for all the variables measured. In the 
BEST study (11), the combination of DMARDs 
and IFX or prednisone showed the best results in 
previously untreated patients with a less than two 
years diagnosis. A study done by the 
Rheumatology Spanish Society (SER) shows that 
the cost of the drug is 56% of the total cost of the 
disease (13). In Spain, the mean annual cost per 
patient is about 5.111€ (between 1.616€ and 
15.345€) (14,15). The data of the current study 
shows a better prognostic in patients treated with 
anti-TNF when there is a low-moderate activity 
of RA. However, an early beginning of BT 
means an increase in cost associated to drugs. 
Therefore, an economic-drug analysis is 
warranted in order to assess whether potential 
improvement in quality of life due to early 
treatment with anti-TNFs provokes a reduction 
in indirect costs higher than the expense of early 
beginning of the treatment. 
One of the disadvantages of the early 
treatment with anti-TNFs, besides the cost of the 
drug, is a higher exposure to these molecules, 
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which can stimulate antibody production (16), 
being one of the factors that could contribute to a 
loss of response (17,18), and therefore, a dose 
increase requirement (19). 
Although the reasons for lack of response 
over time are not clear, it has been observed that 
an increase of the dose or a reduction of the dose 
interval of IFX provides additional benefits to 
these patients (19). Besides, this increasing in the 
dose results in increased cost. On the other hand, 
the spacing strategy is a tool which improves 
efficiency because it reduces the costs associated 
to the drug. In our study, 38.5% of patients were 
treated with a higher interval dose of ETN 
according to label doses. While on the other 
hand, 81.3% of patients with IFX patients use 
higher doses than the ones recommended. These 
results are similar to the ones shown in previous 
studies (14,20). A common pattern between 
patients on spacing therapy has not been found. 
The initial DAS28 has not been associated either 
to the spacing therapy or the time between the 
diagnosis and the starting of treatment with anti-
TNF. However, we should take into account that 
these adjustments have been made randomly by 
the physician. 
An important limitation is that certolizumab 
and golimumab, anti-TNFs used in RA 
treatment, were not studied because at the 
moment of inclusion marketing approvals were 
not yet authorized. Studies evaluating the 5 anti-
TNFs together ought to be done when an enough 
population treated with the new drugs exists. 
Another limitation is that the effectiveness has 
only been measured with the DAS28, other 
parameters such as clinic impression, the Health 
Assessment Questionnaire (HAQ), Rheumatoid 
Factor (RF) or anti-cyclic citrullinated peptides 
(anti-CCP) could have given more information to 
data. 
In conclusion, it is suggested that the early 
treatment with anti-TNF can achieve a higher 
percentage of remissions. Therapeutic spacing is 
established as a strategy to improve efficiency in 
patients in remission, being the ETN the anti-
TNF most susceptible for the spacing, although a 
relation between the early beginning with anti-
TNF and the used dose was not found. However, 
the present data should not be generalized as they 
have been generated from the clinical practice of 
only two hospitals. 
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